Alexion to Present at the 14th Annual Citi Biotech Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Stifel Reiterates Hold Rating on Alexion Pharmaceuticals (ALXN)
August 30, 2019 12:14 PM EDTStifel analyst Paul Matteis reiterated a Hold rating and {REMOVEPT} price target on Alexion Pharmaceuticals (NASDAQ: ALXN)
The analyst comments "While the implications of a theoretical Soliris biosimilar launch (assuming ALXN converts) remain debatable, we expect the IPR institution decision this morning... More
Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133
August 30, 2019 12:00 PM EDTCiti analyst Mohit Bansal reiterated a Buy rating and $150.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).
Analyst is buyer on weakness.Sees FV around $131 to $133 per share.Says while weakness is justified, there is still value in the... More